NIH GUIDE, Volume 21, Number 10, March 13, 1992


P.T. 34


  Disease Model 




National Institute of Allergy and Infectious Diseases

The Respiratory Diseases Branch, Division of Microbiology and

Infectious Diseases, National Institute of Allergy and Infectious

Diseases, has a requirement to develop and characterize an animal model

system with special emphasis on a primate model in which to study the

effects of vaccination of pregnant females on their offspring.  The

long-term goal of the research is to gather evidence for the safety and

efficacy of maternal immunization during pregnancy for the protection

of the newborn by placentally transferred antibody against frequent

infant pathogens.  The purpose of this research effort will be to

provide baseline information, using a primate model, on a minimum of

three candidate vaccines for the maternal immunization approach over

the five-year period of performance.  The theory behind maternal

immunization is that sufficient antibody directed against bacterial or

viral antigens (e.g., type-specific capsular polysaccharides of GBS and

Hib or purified surface proteins of RSV) can protect against systemic

infection and that antibody elicited by vaccination of pregnant women

could confer protection to their infants through placental transfer.

Maternal immunization could, therefore, be viewed as an approach that

might provide short-term passive immunity, obviating the need for

neonatal immunization when it is less likely to be effective.  Indeed,

there is circumstantial evidence that placentally transferred natural

maternal antibody can afford protection to the offspring against

infection with group B Streptococcus types III, Ib, and Ia, Hib, E.

coli K1, N. meningitidis groups A and C and RSV.  Passive protection of

newborns for the first few months of life would bring them into an age

range in which subsequent vaccination could stimulate immunity more


The Request for Proposals NIH-NIAID-DMID-93-02 will be issued on or

about March 24, 1992.  Responses will be due by close of business June

24, 1992.  It is anticipated that a completion-type contract will be

awarded with incremental funding over a period of five years.  Any

responsible offeror may submit a proposal that will be considered by

the Government.  To receive a copy of this RFP, supply this office with

two self-addressed mailing labels.  Telephone inquiries will not be

honored and all inquiries must be in writing and addressed to the

office listed below:

Anthony J. Murray

Contracting Officer, Contract Management Branch

National Institute of Allergy and Infectious Diseases

The Solar Building, Room 3C07

6003 Executive Boulevard

Bethesda, MD  20892

This advertisement does not commit the Government to award a contract.


Return to 1992 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.